Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Cureus ; 15(8): e42821, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-37664326

RESUMO

Percutaneous coronary intervention (PCI) in complex, calcified coronary lesions can be assisted with orbital atherectomy (OA). OA is generally avoided when there are lesions amendable to OA distal to a newly deployed stent due to the risk of device-stent interaction, burr entrapment, and stent avulsion. We present a case documenting the successful passage of an OA system through a recently deployed left main stent to prepare a chronically occluded left anterior descending for PCI.

2.
Cureus ; 13(3): e13910, 2021 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-33880265

RESUMO

Stress-induced cardiomyopathy (SIC) is associated with varying etiologies. We present a case of a 65-year-old female with recurrent SIC secondary to seizures who presented in cardiogenic shock requiring mechanical circulatory support using an Impella CP via the right axillary approach.

3.
Cureus ; 13(2): e13358, 2021 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-33754091

RESUMO

Acute occlusion of the left anterior descending (LAD) coronary artery generally results in ST-segment elevation in the anterior leads of the electrocardiogram and reciprocal ST-segment depression in the inferior leads. We present a case of LAD occlusion presenting as inferior wall ST-segment elevation myocardial infarction.

4.
Coron Artery Dis ; 32(7): 603-609, 2021 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-33587360

RESUMO

BACKGROUND: Myocardial infarction in nonobstructive coronary artery disease (MINOCA) is a recently described infarct subtype. There are few studies that examine coronary artery disease (CAD) extent, MI size and type, and treatment differences at hospital discharge compared to myocardial infarction in obstructive coronary artery disease (MICAD), or that explore sex-specific MINOCA attributes of coronary anatomy and infarct size. METHODS: Our study population consisted of a single tertiary-center of consecutive patients that had coronary angiography for acute MI between 2005 and 2015. The MI type at presentation, MI size and ejection fraction (post-MI), and gender differences between MINOCA patients were examined. RESULT: Among 1698 cases with acute MI, 95 had MINOCA (5.6%). MINOCA patients were younger, more often had NSTEMI, lower peak cardiac troponin (cTn) values, and greater ejection fraction than MICAD patients (all P-values <0.005). At hospital discharge, 30-day re-admission rates were similar. MINOCA patients less frequently received optimal medical therapy. When women were analyzed, the 45 women with MINOCA had smaller MIs (P < 0.001) and greater ejection fraction (P = 0.002) than the 358 women with MICAD. Sex comparisons of the 95 MINOCA patients revealed women were older than men (P < 0.001), had lower mean peak cTn values (P < 0.001), greater ejection fraction (P = 0.02), and more single-vessel disease involvement than men (P < 0.0001). CONCLUSION: The average MI size is smaller in MINOCA than MICAD patients, and there are sex-related differences in clinical presentation, coronary artery disease extent, and MI size. Re-admission rates are similar and MINOCA patients are less likely to receive guideline recommended medical therapy at discharge.


Assuntos
Angiografia/estatística & dados numéricos , Infarto do Miocárdio/diagnóstico por imagem , Fatores Sexuais , Angiografia/métodos , Feminino , Humanos , MINOCA/diagnóstico por imagem , MINOCA/epidemiologia , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/complicações , Estudos Retrospectivos , Fatores de Risco
5.
Future Cardiol ; 15(3): 161-167, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-31148466

RESUMO

Coronary artery to superior vena cava (SVC) fistula is a very rare congenital anomaly of the heart. It typically follows the course of sinoatrial-nodal branch. It can originate from the right coronary or circumflex artery. In the majority of cases, it terminates in the SVC close to the right atrium junction. Only five cases were treated in literature successfully through a transcatheter approach. We present a case with a symptomatic right coronary artery to SVC fistula treated with a unique percutaneous embolization using a guidewire loop/balloon occlusion technique. Controlled access and embolization of the fistula was achieved by through-and-through guidewire access across the coronary fistula from the arterial groin access to the venous groin access with balloon occlusion of the coronary artery fistula while detachable coils were positioned.


Assuntos
Fístula Arteriovenosa/cirurgia , Anomalias dos Vasos Coronários/cirurgia , Vasos Coronários/cirurgia , Procedimentos Cirúrgicos Vasculares/métodos , Veia Cava Superior/anormalidades , Fístula Arteriovenosa/diagnóstico , Cateterismo Cardíaco , Angiografia Coronária , Anomalias dos Vasos Coronários/diagnóstico , Vasos Coronários/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios X , Ultrassonografia de Intervenção , Veia Cava Superior/cirurgia
6.
Future Cardiol ; 15(3): 169-173, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-31148471

RESUMO

Radial artery access is associated with lower bleeding risks and higher patient satisfactions compared with femoral access. It is currently the preferred access for coronary catheterization and interventions, and increasingly used for peripheral and cranial vascular interventions. Herein, we present a patient who had a recent procedures included right transradial right vertebral artery and peripheral vascular interventions. She was admitted for abdominal aortic bifemoral artery bypass, and was complicated with ST elevation myocardial infarction that required immediate cardiac catheterization. Patient did not have palpable radial access and ultrasonography confirmed a total occlusion of right radial artery with thrombus. Although distal right radial artery - at the anatomical snuff box - was not palpable, artery was patent and could be accessed successfully with ultrasonography guidance.


Assuntos
Síndrome Coronariana Aguda/cirurgia , Arteriopatias Oclusivas/complicações , Cateterismo Periférico/métodos , Intervenção Coronária Percutânea/métodos , Síndrome Coronariana Aguda/complicações , Síndrome Coronariana Aguda/diagnóstico , Angiografia , Arteriopatias Oclusivas/diagnóstico , Angiografia Coronária/métodos , Eletrocardiografia , Feminino , Humanos , Pessoa de Meia-Idade , Artéria Radial
7.
Heart Lung ; 48(2): 111-113, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30551803

RESUMO

Right ventricular (RV) dysfunction following surgical implantation of a left ventricular assist device (LVAD) is a well-documented phenomenon, and it is associated with poor outcomes. We are reporting a 25-year-old male patient who presented to the hospital with flu-like symptoms, hypotension and acute hypoxic respiratory failure. The patient's Laboratory data was significant for elevated troponin, and his Chest X-ray showed acute pulmonary edema. Echocardiogram revealed reduced left ventricular (LV) ejection fraction and normal RV function. Coronary angiography was normal, and the cardiac index was 1.3 L/min/m2. Impella 5.0 (Abiomed, MA) was placed through the left axillary artery graft and 4.5 L/min flow was achieved with an improvement in blood pressure. Thirty minutes later, he developed hypotension, the device flow dropped to 3.0 L/min, and right atrial pressure increased. The Pulmonary artery pulsatility index was consistent with RV failure. Possible causes of RV failure include unmasking of RV dysfunction with high LVAD flow and altered RV geometry due to ventricular septum shift. Impella RP (Abiomed, MA) was placed for RV support achieving a flow of 3.8 L/min with a significant improvement in impella LV flow, cardiac output and blood pressure (mean 90 mmHg). Ventricular support devices were weaned off on day 9. The patient was discharged on day 15. Conclusion: our case highlights the risk of RV failure following percutaneous LVAD placement. Early identification and appropriate mechanical support is imperative.


Assuntos
Insuficiência Cardíaca/terapia , Ventrículos do Coração/fisiopatologia , Coração Auxiliar/efeitos adversos , Volume Sistólico/fisiologia , Função Ventricular Direita/fisiologia , Adulto , Remoção de Dispositivo/métodos , Ecocardiografia , Insuficiência Cardíaca/etiologia , Insuficiência Cardíaca/fisiopatologia , Ventrículos do Coração/diagnóstico por imagem , Humanos , Masculino
8.
Heart Lung ; 48(1): 22-27, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30172414

RESUMO

INTRODUCTION: Digitalis has been used for over 200 years to treat patients with heart failure, and evidence supports its use to improve clinical symptoms and quality of life, but not survival. The objective of this retrospective study was to evaluate the effects of digitalis on readmission and mortality in patients with heart failure with reduced ejection fraction (HFrEF) who were receiving current guideline recommended medical therapy. METHODS: We reviewed medical record data from a retrospective cohort study of 1047 patients admitted to the hospital from 2005 to 2014 with decompensated HFrEF. 244 received digitalis, at some point during patient trajectory, and 803 never received digitalis. The primary outcomes of interest were the length of stay in hospital, readmission rates after discharge at 1, 6, 12, and 24 months and the overall mortality rate, at the same time points. RESULTS: We studied the effects of digitalis after adjusting for age, sex, race, potentially confounding comorbidities, and prescription medications. Digitalis treatment is associated with decreases in EF in patients with HFrEF (OR = -2.83, P < 0.001) and was associated with an increased readmission rate for any reason after discharge from the hospital at 6, 12, and 24 months, 53%, 34%, and 35%, respectively. No statistically significant difference was found between patients who received digitalis and those who did not (referent group) for the length of hospital stay and overall mortality rate. CONCLUSION: Digitalis use is associated with increased re-admission rates for any reason following discharge from the hospital at 6, 12, and 24 months.


Assuntos
Digoxina/farmacocinética , Insuficiência Cardíaca/tratamento farmacológico , Readmissão do Paciente/tendências , Qualidade de Vida , Volume Sistólico/fisiologia , Idoso , Cardiotônicos/farmacocinética , Feminino , Insuficiência Cardíaca/metabolismo , Insuficiência Cardíaca/mortalidade , Humanos , Alta do Paciente/tendências , Estudos Retrospectivos , Taxa de Sobrevida/tendências , Estados Unidos/epidemiologia
9.
Cardiovasc Revasc Med ; 19(8S): 25-27, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-29866403

RESUMO

The management of coronary thrombus is not well defined. Current therapies include medical management with anticoagulation, antiplatelet, and thrombolytic therapies or revascularization with percutaneous coronary interventions including mechanical thrombectomy, and coronary artery bypass grafting surgery. In this report, we present a patient with significant left main coronary artery thrombus burden with advanced cirrhosis and recent esophageal variceal bleeding who was successfully treated with conservative medical management.


Assuntos
Trombose Coronária/terapia , Gerenciamento Clínico , Fibrinolíticos/uso terapêutico , Terapia Trombolítica/métodos , Doença Aguda , Idoso , Angiografia Coronária , Trombose Coronária/diagnóstico , Ecocardiografia , Eletrocardiografia , Humanos , Masculino , Ultrassonografia de Intervenção
10.
J Neurol ; 265(3): 578-585, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29356972

RESUMO

BACKGROUND: PFO is more common in cases with cryptogenic stroke compared to cases with no stroke or stroke of identified etiology. Several randomized controlled trials (RCTs) comparing PFO closure with medical therapy have been published with controversial findings. METHODS: PubMed, Embase and Cochrane library databases were searched for RCT comparing PFO closure with medical therapy including antiplatelet therapy (aspirin or clopidogrel or combination) or anticoagulation. We identified 5 trials, including 3627 cases. The mean duration of follow-up was 4 years. Relative risk (RR) and 95% confidence intervals (CI) were calculated using fixed and random-effects models. RESULTS: There was a significant reduction in the incidence of stroke among the PFO closure group compared to medical therapy group, 2.0 versus 4.2%, RR 0.48; 95% CI (0.3, 0.7), p < 0.001. The incidence of AF was higher in the PFO closure group compared to medical therapy group, 4.2 versus 0.7%, respectively, RR 5.9, 95% CI (3, 11), p < 0.001. After exclusion of oral anticoagulants cases (19%), analysis showed a lower incidence of stroke in the PFO closure group (2%) compared to antiplatelet therapy (5.2%), RR 0.4; 95% CI (0.3, 0.6), p < 0.001. There was no significant difference between both groups in the incidence of transient ischemic attacks or all-cause deaths. CONCLUSION: PFO closure results in a significant reduction in the recurrence of ischemic stroke compared to medical therapy alone, primarily antiplatelet, among cases with PFO and cryptogenic stroke.


Assuntos
Forame Oval Patente/complicações , Forame Oval Patente/terapia , Acidente Vascular Cerebral/complicações , Isquemia Encefálica/complicações , Isquemia Encefálica/terapia , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Acidente Vascular Cerebral/terapia
11.
Curr Opin Pharmacol ; 27: 86-91, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26939028

RESUMO

The development of a new generation of non-vitamin K oral anticoagulants represents a potential breakthrough in the management of patients with thrombotic diseases, disorders and conditions. While a large and growing body of evidence from large-scale clinical trials and registries supports a favorable safety profile, having a means to rapidly reverse their anticoagulant effects represents an unmet need among practicing clinicians. Several targeted reversal agents are currently in development and the early results are promising. Idarucizumab is a monoclonal antibody that can immediately and specifically reverse dabigatran. Andexanet alfa is a recombinant modified factor Xa that can bind and reverse oral and parenteral factor Xa inhibitors, including rivaroxaban, apixaban and edoxaban, and low molecular weight heparin. Aripazine is a small molecule that can reverse the action of factor Xa inhibitors and possibly dabigatran as well through non-covalent binding and charge-charge interactions.


Assuntos
Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Administração Oral , Animais , Fator Xa/metabolismo , Inibidores do Fator Xa/farmacologia , Inibidores do Fator Xa/uso terapêutico , Humanos , Trombose/tratamento farmacológico
12.
J Cardiol Cases ; 13(2): 56-59, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30524556

RESUMO

Single ostium coronary artery is a rare coronary artery anomaly. It is reported to occur in only 0.0448% of cases who underwent invasive coronary angiography. It can be associated with angina, arrhythmias, and possibly sudden death and is a clinically important entity to rule out in patients presenting with chest pain. We report the case of a 68-year old man who presented with worsening resting chest pain and underwent invasive coronary angiography and a single ostium coronary artery was identified. Subsequent coronary computed tomography (CT) angiography revealed it to be a unique variation of class R-III of Lipton classification of single ostium coronary artery. Lipton R-III single ostium coronary artery is rare and its incidence is reported to be 0.004% in patients who had invasive coronary angiography. In our case, anomalous left coronary circumflex artery was retroaortic course combined with intramyocardial course. It also divided into multiple obtuse marginal branches in the myocardium and never coursed along the anterior and lateral aspects of the arterioventricular groove. This variation has not been reported in the literature. Coronary CT angiography played an essential role to delineate this complex coronary anomaly. .

13.
J Cardiovasc Electrophysiol ; 26(9): 1027-1037, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26075595

RESUMO

Atrial fibrillation (AF) is the most common chronic arrhythmia in the adult population. Ablation lines have largely replaced the historical and challenging cut and sew techniques. Surgical ablation of AF is commonly performed in cases with other indications for cardiac surgery and less commonly as a stand-alone therapy. Pulmonary vein isolation is the cornerstone of this procedure. Extended left atrial ablation lines may increase efficacy in cases with longstanding persistent or permanent AF. Additional efficacy by adding right atrial ablation is controversial but is often performed in cases undergoing right atrial or atrial septal surgery. Left atrial volume reduction is recommended in cases with large left atria and AF undergoing another cardiac surgery. Arrhythmia recurrence is not uncommon after surgical ablation of AF and varies among studies due to heterogeneity in patient population, lesion set and endpoints. Freedom from AF recurrence was 65-87% at 12 months and 58-70% at 2 years follow-up. Long-term monitoring is recommended due to an increased prevalence of asymptomatic recurrences. The strongest predictors of AF recurrence are longstanding or persistent AF and a large left atrium. The most common mechanisms of recurrence are pulmonary vein reconnection, nonpulmonary vein triggers, and gaps in the ablation lines. About 20% of atrial tachyarrhythmia recurrences are atrial flutter or atrial tachycardia. There are not enough data in the surgical literature to support withdrawal of anticoagulation after surgical AF ablation. Patients selected for stand-alone surgical ablation usually have low risk profiles and low postoperative mortality rates (0.2%).

14.
Cardiovasc Ther ; 33(5): 253-63, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26010419

RESUMO

INTRODUCTION: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent implantation (DES) is not certain. The AHA/ACC guidelines recommend 12 months of DAPT based on observational trials. Recently, several large randomized controlled trials (RCT) suggested a noninferiority of shorter duration of DAPT and other trials showed a benefit from extended duration of DAPT after 12 months of DES implantation. METHODS: PubMed databases were searched for RCTs comparing the continued use of DAPT to shorter duration of DAPT (aspirin alone) for variable durations beyond 3 months of DES implantation. Our analysis was limited to trials with clinical outcomes. Odds ratio (OR) and 95% confidence intervals (CI) were calculated using fixed and random-effects models. Subgroup analyses were performed for second generation DES and for trials comparing 12 months of DAPT vs. earlier interruption or longer duration of DAPT. RESULTS: We identified 10 RCTs including 32,136 subjects randomized to continued use of DAPT vs. aspirin alone for variable durations after 3 months of DES implantation. There was no significant heterogeneity among studies (Q test P > 0.1). Compared to shorter DAPT, longer DAPT resulted in a significant reduction in stent thrombosis (0.3% vs. 0.7%, P < 0.01) and myocardial infarction (1.3% vs. 2%, P < 0.01), and a significant increase in major bleeding (0.8% vs. 0.4%, P < 0.01). There was no difference in cardiac deaths or stroke. All-cause deaths were slightly lower with shorter DAPT compared to longer DAPT (OR 0.8, 95% CI 0.7 to 0.99, P = 0.04). A small number of subjects were included between 3 and 6 months after DES implantation. CONCLUSION: DAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone). There was no difference in cardiac mortality or stroke.


Assuntos
Stents Farmacológicos , Intervenção Coronária Percutânea/métodos , Inibidores da Agregação Plaquetária/administração & dosagem , Aspirina/administração & dosagem , Aspirina/efeitos adversos , Intervalos de Confiança , Esquema de Medicação , Quimioterapia Combinada , Hemorragia/induzido quimicamente , Humanos , Infarto do Miocárdio/prevenção & controle , Razão de Chances , Inibidores da Agregação Plaquetária/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Trombose/prevenção & controle , Fatores de Tempo
15.
J Card Surg ; 30(7): 619-21, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25976163

RESUMO

We report a case of pulmonary vein stenosis following a standalone minimally invasive surgical ablation for atrial fibrillation. The etiology, diagnosis, and management of this complication are the subject of this review.


Assuntos
Fibrilação Atrial/cirurgia , Ablação por Cateter/métodos , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Complicações Pós-Operatórias , Pneumopatia Veno-Oclusiva , Seguimentos , Insuficiência Cardíaca , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/diagnóstico , Atelectasia Pulmonar , Pneumopatia Veno-Oclusiva/diagnóstico , Recidiva
16.
Am J Case Rep ; 16: 140-5, 2015 Mar 08.
Artigo em Inglês | MEDLINE | ID: mdl-25746428

RESUMO

BACKGROUND: We herein report a case of huge pulmonary artery aneurysm in a 55-year-old male farmer from the Nile delta (Lower-Egypt), mostly due to infestation with Schistosoma mansoni, which is the parasite causing hepatosplenic schistosomiasis. CASE REPORT: This male patient was admitted with a month-long history of progressive shortness of breath, 2-month history of fever, and a cough with mucoid sputum for 10 days. On examination, he had normal temperature and blood pressure, but he had tachypnea, tachycardia, and congested neck veins. Electrocardiography showed multifocal atrial tachycardia and right bundle branch block. CONCLUSIONS: The present case is unique in that it shows the presence of a huge pulmonary artery aneurysm despite the absence of pulmonary hypertension.


Assuntos
Aneurisma/diagnóstico , Hepatopatias Parasitárias/complicações , Artéria Pulmonar , Embolia Pulmonar/etiologia , Esquistossomose mansoni/complicações , Esplenopatias/complicações , Aneurisma/etiologia , Evolução Fatal , Humanos , Hipertensão Pulmonar , Hepatopatias Parasitárias/diagnóstico , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar/diagnóstico , Esquistossomose mansoni/diagnóstico , Esplenopatias/diagnóstico , Esplenopatias/parasitologia
18.
Clin Cardiol ; 37(7): 417-21, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25043948

RESUMO

BACKGROUND: Patients with chronic kidney disease (CKD) are at increased risk of life-threatening cardiovascular arrhythmias. Although these arrhythmias are usually secondary to structural heart diseases that are commonly associated with CKD, a significant proportion of cases with sudden cardiac death have no obvious structural heart disease. This study aims to explore the relationship of cardiac repolarization in patients with CKD and worsening kidney function. HYPOTHESIS: There is cardiac repolarization abnormalities among patients with chronic kidney disease. METHODS: This was a retrospective, chart-review study of admissions or clinic visits to a university hospital between 2005 and 2010 by patients with a diagnosis of CKD. Inclusion criteria selected patients who had 12-lead surface electrocardiography (ECG), renal function tests within 24 hours, and transthoracic echocardiography within 6 months. Cases with a documented etiology for the corrected Qt (Qtc) interval prolongation including structural heart disease, QT prolonging drugs, or relevant disease conditions, were excluded. RESULTS: Our sample size was 154 ECGs. Two-thirds of patients with CKD had QTc interval prolongation, and about 20% had a QTc interval >500 ms. QTc interval was significantly different and increased with each successive stage of CKD using the Bazett (P < 0.006) or Fridericia (P = 0.03) formula. QTc interval correlated significantly with serum creatinine (P = 0.01). These finding were independent of age, gender, potassium, and calcium concentrations. CONCLUSIONS: The progression of CKD resulted in a significant delay of cardiac repolarization, independent of other risk factors. This effect may potentially increase the risk of sudden cardiac death, and may also increase the susceptibility of drug-induced arrhythmia.


Assuntos
Arritmias Cardíacas/etiologia , Sistema de Condução Cardíaco/fisiopatologia , Rim/fisiopatologia , Insuficiência Renal Crônica/complicações , Potenciais de Ação , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatologia , Progressão da Doença , Ecocardiografia , Eletrocardiografia , Feminino , Hospitais Universitários , Humanos , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/etiologia , Síndrome do QT Longo/fisiopatologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Insuficiência Renal Crônica/diagnóstico , Insuficiência Renal Crônica/fisiopatologia , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo
19.
J Thromb Thrombolysis ; 37(3): 372-9, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24515754

RESUMO

Vitamin K antagonists have been the only available oral anticoagulant therapy for decades until the recent introduction of novel (new) oral anticoagulants. This breakthrough provides patients with alternative treatment choices that have predictable pharmacokinetics and do not require routine coagulation monitoring. Though more convenient from patient perspective, these drugs have distinct pharmacological properties that are particularly important to recognize when transitioning anticoagulant therapies. The following review focuses on transitioning to and from the novel oral anticoagulants, employing a practical pharmacokinetic- and pharmacodynamic-based approach.


Assuntos
Anticoagulantes/uso terapêutico , Monitorização Fisiológica/métodos , Vitamina K/antagonistas & inibidores , Administração Oral , Anticoagulantes/farmacocinética , Coagulação Sanguínea/efeitos dos fármacos , Humanos
20.
Cardiovasc Ther ; 32(1): 19-25, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24428853

RESUMO

This review aims to clarify the underlying risk of arrhythmia associated with the use of macrolides and fluoroquinolones antibiotics. Torsades de pointes (TdP) is a rare potential side effect of fluoroquinolones and macrolide antibiotics. However, the widespread use of these antibiotics compounds the problem. These antibiotics prolong the phase 3 of the action potential and cause early after depolarization and dispersion of repolarization that precipitate TdP. The potency of these drugs, as potassium channel blockers, is very low, and differences between them are minimal. Underlying impaired cardiac repolarization is a prerequisite for arrhythmia induction. Impaired cardiac repolarization can be congenital in the young or acquired in adults. The most important risk factors are a prolonged baseline QTc interval or a combination with class III antiarrhythmic drugs. Modifiable risk factors, including hypokalemia, hypomagnesemia, drug interactions, and bradycardia, should be corrected. In the absence of a major risk factor, the incidence of TdP is very low. The use of these drugs in the appropriate settings of infection should not be altered because of the rare risk of TdP, except among cases with high-risk factors.


Assuntos
Antibacterianos/efeitos adversos , Torsades de Pointes/induzido quimicamente , Animais , Interações Medicamentosas , Eletrocardiografia/efeitos dos fármacos , Fluoroquinolonas/efeitos adversos , Humanos , Macrolídeos/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA